Independent intelligence for the laboratory world

MedMira Syphilis Test Receives FDA Breakthrough Device Designation

MedMiraโ€™s combined treponemal and non-treponemal syphilis antibody test received FDA Breakthrough Device designation.

MedMira Multiplo Complete Syphilis TP/nTP point-of-care antibody test. Image courtesy of MedMira.

Press release summary

HALIFAX, Nova Scotia โ€” MedMira said Nov. 17 that the U.S. Food and Drug Administration granted Breakthrough Device designation to its Multiplo Complete Syphilis TP/nTP Antibody Test.

The point-of-care test uses the companyโ€™s Rapid Vertical Flow technology to detect treponemal and non-treponemal antibodies from a single fingerstick whole-blood specimen. Conventional syphilis testing commonly combines these two antibody approaches to identify exposure and help assess active infection, often through separate laboratory procedures.

MedMira said the combined format is intended for settings that may have limited access to conventional laboratory infrastructure, including community health centers, outreach programs and remote locations. The companyโ€™s product page says the test remains in clinical trials in Canada and is not yet approved there.

Why it matters: A rapid combined antibody test could reduce repeat visits and shorten the path from screening to clinical follow-up, especially where laboratory access is limited. Breakthrough Device designation provides additional FDA interaction and potentially prioritized review. It does not constitute FDA clearance or approval, and the release did not provide a U.S. launch date or complete clinical-performance data.

Read MedMiraโ€™s original Nov. 17 release.

Join the Discussion

Share your experience or ask a question about this article. Please keep comments relevant and respectful.

Leave a Reply

Your email address will not be published. Required fields are marked *